Stockscreener 앱 받기
1.15%
시간 외 거래:
전일 마감가:
$345.60
열려 있는:
$348.76
하루 거래량:
3.45M
Relative Volume:
1.35
시가총액:
$188.67B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
24.31
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
+3.80%
1개월 성능:
+6.07%
6개월 성능:
+5.97%
1년 성능:
+21.76%
1일 변동 폭
$347.66
$356.50
1주일 범위
$322.30
$356.50
52주 변동 폭
$267.83
$391.29
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
349.58 | 186.52B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Does Amgen Stock's Recent Strength Signal Real Portfolio Diversification? - Trefis
Amgen (NASDAQ:AMGN) Cut to Hold at Wall Street Zen - MarketBeat
Amgen: A Biotech Giant's Path to Recovery and Growth - The Globe and Mail
Is Amgen An Undervalued Stock Or Value Trap? - Yahoo Finance
Amgen Inc. (AMGN) Announces EC’s Grant of Marketing Authorization for IMDYLLTRA® - Insider Monkey
Key Study for Amgen’s Tavneos Under Investigation at Journal - Bloomberg.com
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Goldman Sachs Maintains Amgen(AMGN.US) With Buy Rating, Cuts Target Price to $389 - Moomoo
Is There Still Opportunity In Amgen (AMGN) After Its 24% One-Year Share Price Gain - simplywall.st
Is Oncology Approval And Autoimmune Data Momentum Altering The Investment Case For Amgen (AMGN)? - Yahoo Finance
Amgen: Time For An Upgrade? Yes, I Think So (NASDAQ:AMGN) - Seeking Alpha
Harvest Fund Management Co. Ltd Has $15.85 Million Holdings in Amgen Inc. $AMGN - MarketBeat
TD Asset Management Inc Has $120.20 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Acquired by Daiwa Securities Group Inc. - MarketBeat
Cibc World Market Inc. Acquires 7,112 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Touts MariTide, AI Gains and 2026 Growth Plans at Jefferies Conference - MarketBeat
Amgen Won't Face 'Nonsensical' Rodent Antibody IP At Trial - Law360
Real-World Evidence: Shaping Obesity Treatment Beyond Clinical Trials - Amgen
kidSTREAM Opening Brings Hands-On Science Learning to Families Near Amgen’s Headquarters - Amgen
Amgen Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Amgen CFO and markets chief speak at Goldman Sachs healthcare event - Stock Titan
Amgen Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
A Look at Amgen Inc (AMGN) After 3.0% Gain -- GF Value $353.21 v - GuruFocus
Archvest Wealth Advisors Inc. Buys Shares of 3,801 Amgen Inc. $AMGN - MarketBeat
28,909 Shares in Amgen Inc. $AMGN Acquired by Avalon Capital Management - MarketBeat
Assessing Amgen (AMGN) Valuation After Imdelltra Approval And Concerns Over Tavneos And Prolia - simplywall.st
Bob Bradway on AI: Reimagining the Future of Biotechnology - Amgen
Amgen Inc Stock (AMGN) Closed Up by 3.04% on Jun 3: Key Drivers Unveiled - TradingKey
Amgen Inc. stock (US0311621009): EU lung cancer approval draws focus as shares hold near USD 330 - AD HOC NEWS
Rare autoimmune drugs UPLIZNA and TAVNEOS show control with fewer steroids - Stock Titan
Oncolytic Virus Cancer Therapy Market Led by U.S. as Amgen and CG Oncology Advance Innovation - openPR.com
Amgen Shareholder Notice - TMX Newsfile
Natixis Advisors LLC Has $113.26 Million Holdings in Amgen Inc. $AMGN - MarketBeat
CIBC Asset Management Inc Buys 44,110 Shares of Amgen Inc. $AMGN - MarketBeat
Bridges Investment Management Inc. Lowers Holdings in Amgen Inc. $AMGN - MarketBeat
Bank of New York Mellon Corp Trims Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN): Company Profile, Stock Price, News, Rankings - Fortune
EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus - simplywall.st
Amgen (AMGN) Secures EU Approval for Imdelltra in Small Cell Lun - GuruFocus
Amgen Inc. stock (US0311621009): EU approves Imdylltra as shares ease from recent highs - AD HOC NEWS
The Next Era in Obesity Care - Amgen
Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication - Yahoo Finance
ANCA Vasculitis Market to Witness Transformational Growth - openPR.com
EC approval for Amgen’s Imdylltra - The Pharma Letter
BNP Paribas Acquires 38,554 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Inc. stock (US0311621009): EU approval for IMDYLLTRA adds fresh catalyst - AD HOC NEWS
Amgen's Extensive-stage Small Cell Lung Cancer Immunotherapy Granted EU Marketing Authorization - Moomoo
Amgen Inc. stock underperforms Monday when compared to competitors - MarketWatch
EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER - PR Newswire
Amgen Inc. stock (US0311621009): Shares open lower in New York - AD HOC NEWS
Amgen shares dip amid rising selling pressure - Traders Union
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.81%
1.36%
자본화:
|
볼륨(24시간):